openPR Logo
Press release

Dilated Cardiomyopathy Therapeutics Market Research Report Forecast

06-30-2017 01:38 PM CET | Health & Medicine

Press release from: Transparency Market Research

Dilated Cardiomyopathy Therapeutics Market

Dilated Cardiomyopathy Therapeutics Market

A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the existing as well as new players in this market in designing their business strategies.According to the research study, in 2013, the global dilated cardiomyopathy therapeutics market was valued at US$651 mn and is anticipated to decline to US$328.6 mn by the end of 2020. This market is projected to exhibit -7% CAGR between 2014 and 2020.

The growing prevalence of congestive heart failure is the only key factor that is driving the demand for dilated cardiomyopathy therapeutics; however, there are many factors that are expected to hamper the growth of this market in the forecast period. Easy availability of pacemakers, implantable cardioverter defibrillators, promising developments in gene therapy, and implantable devices such as heart pumps are the factors curbing the growth of the dilated cardiomyopathy therapeutics market. In addition, the various side effects associated with the use of dilated cardiomyopathy therapeutics and other easier therapies using devices that have negligible side effects will hold back the growth of this market in the next few years.

This 90 page report gives readers a comprehensive overview of the Dilated Cardiomyopathy Therapeutics Market. Unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

On the basis of drug class, the global market for dilated cardiomyopathy therapeutics has been classified into aldosterone antagonists, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. By pipeline drugs, the market has been segmented into ARRY-797, CAP-1002, MYDICAR, ixCELL-DCM, and OR-1. A detailed analysis of these segments has been presented in the research report.

The global dilated cardiomyopathy therapeutics market has been divided on the basis of geography into Europe, North America, Asia Pacific, and Rest of the World. In 2013, North America accounted for the largest share of the market owing to the growing adoption of branded drugs, and the rising occurrence of congestive heart failure. In the U.S., dilated cardiomyopathy strikes around five to eight people amongst every 100,000. Asia Pacific and the Rest of the World markets for dilated cardiomyopathy therapeutics are growing at a fast pace owing to the increasing per capita income, improving economic standards, and rising demand for generic drugs.

Get accurate market forecast and analysis on the Dilated Cardiomyopathy Therapeutics Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

Furthermore, the research report covers the competitive landscape of the global dilated cardiomyopathy therapeutics market including an overview of leading companies, their product portfolio, financial overview, business strategies, recent developments, and SWOT analysis. Some of the prominent players operating in the global market for dilated cardiomyopathy therapeutics are Novartis International AG, Celladon Corporation, Sanofi S.A., Vericel Corporation, AstraZeneca plc, Pfizer, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Janssen Pharmaceuticals, Inc., and Array BioPharma, Inc.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dilated Cardiomyopathy Therapeutics Market Research Report Forecast here

News-ID: 602973 • Views:

More Releases from Transparency Market Research

Biohydrogen Industry Expected to Reach USD 146.7 Million by 2034 on the Back of Climate Initiatives & Fossil Fuel Constraints - TMR Insights
Biohydrogen Industry Expected to Reach USD 146.7 Million by 2034 on the Back of …
The global biohydrogen industry, valued at US$ 73.4 million in 2023, is projected to grow at a CAGR of 6.5% from 2024 to 2034, reaching an estimated US$ 146.7 million by the end of the forecast period. Increasing concerns over climate change and the environmental impact of fossil fuels are at the forefront of the biohydrogen market's expansion. As conventional petroleum reserves dwindle, the shift toward green hydrogen produced from renewable
Shore Power Market Set to Surpass USD 3.3 Billion by 2031 on the Back of Port Upgrades & Regulatory Incentives - TMR Report
Shore Power Market Set to Surpass USD 3.3 Billion by 2031 on the Back of Port Up …
The global shore power industry, valued at US$ 1.4 billion in 2022, is projected to advance at a CAGR of 10.2% from 2023 to 2031, reaching an estimated US$ 3.3 billion by the end of the forecast period. Shore power-also known as cold ironing or on-shore power supply-enables vessels at berth to connect with onshore electrical grids, reducing reliance on shipboard generators and significantly cutting emissions. The rising number of ports
Global Fusion Power Market Poised to Surpass USD 645.1 Billion by 2034, Backed by Government Initiatives & Clean Energy Trends - TMR Analysis
Global Fusion Power Market Poised to Surpass USD 645.1 Billion by 2034, Backed b …
The global fusion power industry, valued at US$ 300.0 billion in 2023, is projected to grow at a CAGR of 7.2% from 2024 to 2034, reaching an estimated US$ 645.1 billion by the end of the forecast period. The increasing need for clean energy amid depleting fossil fuels and rising environmental concerns has spurred substantial interest in nuclear fusion. Governments worldwide are significantly boosting their investments in alternative energy sources by
Large-scale LNG Terminals Market Set to Reach USD 3.2 Billion by 2031 on the Back of Clean Energy Uptake & Infrastructure Spending - TMR Report
Large-scale LNG Terminals Market Set to Reach USD 3.2 Billion by 2031 on the Bac …
The global large-scale LNG terminals industry(https://www.transparencymarketresearch.com/largescale-lng-terminals-market.html), valued at US$ 2.3 billion in 2022, is projected to grow at a CAGR of 3.9% from 2023 to 2031, reaching an estimated US$ 3.2 billion by the end of the forecast period. The surge in demand for clean energy sources, driven by heightened environmental concerns and the need to reduce carbon emissions, is a key factor behind the expanding market for large-scale LNG terminals.

All 5 Releases


More Releases for Dilated

Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end
Dilated Cardiomyopathy Market Opportunity Analysis, 2026 – 2026
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy Market – Global Industry Insights,2025
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy - Pipeline Review, H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2017, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing,
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast to 2020
Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1. Keen players in
Autoimmunity in myocarditis and dilated cardiomyopathy
Autoimmune Diseases: "Myocarditis is an acquired inflammatory condition involving the myocardial tissue. Although myocarditis is largely associated with viral infections, some cases remain idiopathic, while in others there is convincing evidence of autoimmune pathophysiology. Autoimmunity is influenced by genetic, immune, hormonal and environmental factors. Myocardial injury (due to infection, ischaemia, inflammation, toxins or other cardiotoxic factors) may trigger exposure to autoantigens, subsequently, initiating an autoimmune response, causing myocarditis and dilated